20 results about "Lung deposition" patented technology

The invention discloses an inhalation administration device and a design method, and mainly relates to the technical field of medical instruments. The device comprises a capsule base, a capsule body, a capsule cabin and a suction nozzle, an inner cavity of the suction nozzle is of an inverted trapezoid structure, and in other words, the diameter of the section is increased by 0.033 mm every time the inner area of the suction nozzle is raised by 1 mm from the bottom end to the top end. According to the design, by optimizing the internal flow field of the suction nozzle, the dispersity of medicine particles can be remarkably improved, wall surface deposition is reduced, and therefore the dispersity of the medicine particles and the lung deposition efficiency are improved. The invention also provides a design method based on lattice Boltzmann method-immersion boundary method-large eddy simulation multi-physics field coupling numerical simulation, and by setting specific performance evaluation parameters, the structure optimization of the inverted trapezoidal suction nozzle can be efficiently and accurately guided. An in-vitro deposition test shows that the performance of the device is superior to or equivalent to that of a commercially available product.

An innovative imaging-based subject-specific whole-lung deposition model is provided. Computed tomography (CT) lung volumetric images at total lung capacity (TLC) may be used to segment airways and lobes, and registration of CT images at TLC and functional residual capacity (FRC) provided metrics of regional air volume changes. A volume-filling technique may then be used to generate the entire conducting airways and acinar units. In each acinar unit, a respiratory airway model may be generated based on existing morphometric data. The flow distributions in conducting airways and to acinar units may be calculated by a one-dimensional (ID) computational fluid dynamics (CFD) model. With the simulated airflow field, deposition fractions may be calculated using deposition probability formulae adjusted with an enhancement factor to account for the effects of transient secondary flow and realistic airway geometry.

The present invention relates to an atomizing device, which comprises: an atomizing chamber; and an aerosol output channel, connecting the atomizing chamber with the external environment; wherein, the conveying direction of at least part of the aerosol output channel intersects with the air inlet direction of the aerosol output channel, and / or the conveying direction of at least part of the aerosol output channel intersects with the air outlet direction of the aerosol output channel. In the above-mentioned atomizing device, the aerosol particles flowing through the aerosol output channel undergo irregular motion, thereby increasing the probability of aerosol particles colliding with each other, and aerosol particles with smaller particle sizes combine to form aerosol particles with larger particle sizes, thereby effectively reducing the proportion of aerosol particles with a particle size of approximately 0.62 μm and 0.78 μm, and increasing the proportion of aerosol particles with a particle size of approximately 1.32 μm. Therefore, most of the aerosol particles output by the atomizing device of the present application have a particle size of 1 μm-5 μm, have a high lung deposition rate, and effectively improve the effective utilization of the active ingredients in the aerosol.

The invention belongs to the technical field of biological medicines, and particularly provides an ALO-coated F127-MOF nano-composite as well as a preparation method and application thereof. According to the ALO (at) F127-MOF nano compound, UiO-66-NH2 MOF with a pluronic F-127 coating is used as a nano carrier, and aloperine is loaded on the nano carrier. The nano compound is used for treating ALI, the solubility, stability and bioavailability of the traditional Chinese medicine aloperine are effectively improved, and the synergistic effect of sustained release of aloperine, ROS neutralization and effective targeting is achieved. The aerosolization-based delivery approach ensures better oxygenation, lower systemic toxicity, and better pulmonary deposition. The invention provides a new treatment method for noninvasive acute lung injury treatment.

Provided in the present invention are a suspended triple inhalation aerosol composition and a preparation method therefor. The aerosol composition comprises fluticasone furoate, vilanterol trifenatate, glycopyrrolate, a diluent, a surfactant and a propellant; has higher drug-delivery efficiency and drug-delivery dose, and higher lung deposition; and has the effects of better ameliorating Mch-induced elevated pulmonary resistance and decreased pulmonary compliance, thereby facilitating improvement to medication safety and patient compliance.

The invention belongs to the technical field of atomizers, and relates to a metal atomization sheet for medical atomization and a manufacturing method. Comprising a metal sheet, the metal sheet is circular, a plurality of micropores are uniformly formed in the center of the metal sheet, and the micropores are trumpet-shaped. The metal atomizing sheet adopts a circular design, so that the metal atomizing sheet can be better matched with the internal structure of the vibrating screen hole atomizer, is convenient to mount and fix, and improves the convenience of assembly and the stability of the structure. And the micropores are formed in the center of the metal sheet and are uniformly distributed, so that the medicine can uniformly pass through the micropores in the vibration process, local blockage or non-uniform atomization is avoided, and the consistency and stability of atomized particles are ensured. The micropores are designed in a horn shape, and the gradually-expanded structure of the micropores is beneficial to forming a more stable gas-liquid interface when the medicine passes through, reducing the flow resistance, improving the atomization efficiency and the uniformity of atomized particles, and being beneficial to deposition of the medicine in the lung.

The invention discloses a rifapentine capsule type dry powder inhaler and a preparation method thereof, the capsule type dry powder inhaler comprises a capsule shell and a capsule content, and the capsule content comprises the following components in parts by weight: 1 part of rifapentine, 1-30 parts of a carrier and 0.01-1 part of a flow aid. According to the invention, micronized drug bulk drugs and appropriate excipients are in the form of capsules, and atomized drugs are actively inhaled into the lungs by a patient through a specially-made dry powder inhalation device. The delivery efficiency of the preparation is high, and the lung deposition rate is high; the particle size of the preparation and the stability of the preparation are high, and the compatibility between raw materials and auxiliary materials is good. The rifapentine capsule type dry powder inhaler disclosed by the invention has no gastrointestinal tract degradation effect and no liver first-pass effect, the medicine can directly act on the lung, the absorption is quick, and the effect is quick after administration; meanwhile, local administration is realized, the dosage is obviously reduced, and toxic and side effects are small. The preparation method disclosed by the invention is simple and easy to implement, has no too high requirements on technical equipment, and is suitable for domestic industrial production.

The invention provides a fluticasone furoate micellar solution. The fluticasone furoate micellar solution comprises fluticasone furoate, a lipophilic component and a nonionic surfactant. According to the fluticasone furoate pharmaceutical composition, the dissolution rate and the absorption rate of fluticasone furoate on nasal mucosa and alveolar mucosa can be remarkably improved, and the administration dosage can be further reduced while the same curative effect is obtained, so that the toxic and side effects are reduced. The aerosol inhalation powder is especially suitable for aerosol inhalation, can provide better pulmonary deposition, and is especially suitable for nasal administration to reduce the administration dosage and improve the bioavailability.

The invention belongs to the field of pharmaceutical preparations, and provides an auxiliary material system for pulmonary administration of insoluble drugs and a preparation method of the auxiliary material system. According to the invention, a collaborative design of lipid-coated indissolvable drug nanocrystal core-shell particles and a ternary lipid dispersion intermediate is adopted, and an anti-solvent precipitation in-situ coating and high-pressure microjet refining technology is adopted; the preparation method comprises the following steps: coating the outer surface of a nintedanib nanocrystal with a lipid shell layer composed of dipalmitoyl-sn-glycerol-3-phosphorylcholine, cholesterol and propylene glycol caprylate to form core-shell particles with the mass median particle size D50 value of 150-250 nm and the volume distribution D90 value of less than or equal to 400 nm. According to the invention, high drug loading capacity, low viscosity and atomizable property are realized, lung deposition distribution and long-term particle size stability are optimized, the contradiction between high solid content and rheological property, low irritation and colloid stability, and atomization efficiency and core-shell structure integrity in lung administration of insoluble drugs is effectively relieved, and the preparation method has wide clinical application value.

The invention relates to the technical field of medicines, in particular to an inhalable pharmaceutical composition containing a soluble guanylate cyclase (SGC) receptor stimulant and application of the inhalable pharmaceutical composition, and clinical adverse reactions of medicines can be remarkably reduced. According to the pharmaceutical composition, the administration dosage is reduced, on the premise that the drug effect is kept unchanged, the hypotension side effect caused in the administration process is reduced, and the normal blood pressure level is rapidly recovered after administration. The pharmaceutical composition provided by the invention needs to be combined with matched instruments for use, wherein the pharmaceutical composition comprises an SGC receptor stimulant drug and other inhalable pharmaceutic adjuvants. The lung deposition rate can reach more than 40% under the combination of a specific prescription and instruments. Through inhalation of the pharmaceutical composition, an SGC receptor stimulant can enter blood more quickly, and pharmacokinetic parameters such as Tmax are improved.

The invention relates to the technical field of medicines, and discloses a lung anti-inflammatory spray based on aloe polysaccharide, which realizes efficient anti-inflammatory (IL-6) and targeted delivery (deposition rate of 85%) by optimizing the proportion of natural components (8% of aloe polysaccharide, 1.5% of dipotassium glycyrrhizinate and 2% of andrographolide) and an atomization process (particle size of 2 mu m). According to the lung anti-inflammatory spray based on the aloe polysaccharide and the preparation method of the lung anti-inflammatory spray, through the synergistic effect of the aloe polysaccharide (8%) and natural anti-inflammatory components (1.5% of dipotassium glycyrrhizinate and 2% of andrographolide), the proinflammatory factor level (IL-6 is reduced by 60%, and TNF-alpha is reduced by 62%) is remarkably reduced, the inhibition rate on an LPS-induced mouse pneumonia model reaches 88% or above, and the lung anti-inflammatory spray has the advantages that the lung anti-inflammatory spray has a good application prospect. The effect of the dexamethasone spray is better than that of a single-component or chemically synthesized drug (such as dexamethasone), drug particles are efficiently deposited in an alveolar area through an optimized atomization process (the spraying particle size is 2 microns), the lung deposition rate is larger than or equal to 85% and far exceeds that of a conventional spray (generally smaller than or equal to 70%), and the bioavailability is remarkably improved.

The invention relates to the technical field of biological medicine, and discloses a lung targeting mRNA delivery construction method based on particle size control, which comprises the following steps: selecting a nano carrier material with biocompatibility and adjustable property; designing and modifying the nano-carrier material, and endowing the nano-carrier material with specific functional groups; and establishing a mathematical physical model, calculating the deposition behavior of the particles in the airflow based on fluid mechanics and particle dynamics theories, and calculating the deposition efficiency of the particles in the lung according to the particle size. The micro-fluidic technology and the temperature and pH response type polymer are combined, the particle size is accurately adjusted, the particle size can be controllably changed in different physiological environments, and the precision and flexibility of particle size distribution are improved. Adaptive optimization is carried out through simulated annealing and a genetic algorithm, lung deposition, cellular uptake and carrier stability are comprehensively considered, and the delivery efficiency is maximized. The model established by combining fluid mechanics and particle dynamics theories optimizes the relationship between the particle size and the cellular uptake efficiency.

Provided is a computer implemented method for determining airway deposition of an inhaled substance in a zone of a lung of a subject, comprising: —receiving a patient dataset of the subject comprising a parameter set of two or more parameters and corresponding values, wherein the parameters in the parameter set form at least four dimensionless numbers in a dimensionless correlation specific to the zone, —determining, from the dimensionless correlation and the corresponding values of the parameters in the parameter set, the airway deposition of the inhaled substance in the zone of the lung of the subject.

The invention discloses an intelligent electric dosing device applied to a pressure quantitative aerosol, and aims to solve the problems of difficulty in hand-mouth coordination and low medicine utilization rate in use of the traditional pressure quantitative aerosol (pMDI). The device comprises a shell, a mouthpiece, a medicine bottle fixing mechanism, an electric driving mechanism, an air suction detection module and a control module. The medicine bottle fixing mechanism is movably arranged on the shell and used for fixing a medicine bottle in a repeatable assembling and disassembling mode and enabling a medicine bottle nozzle to be aligned with and stretch into an air inlet of the mouthpiece. The electric driving mechanism is used for driving the medicine bottle fixing mechanism to move to extrude the nozzle to release medicine; the inspiration detection module is used for detecting the inspiration action of a patient; the control module automatically controls the electric driving mechanism to execute pesticide spraying according to the air suction signal. By means of an air suction synchronous automatic triggering mechanism, the medicine taking correctness and the medicine lung deposition rate are remarkably improved.

The invention discloses an aerosol inhalation preparation based on traditional Chinese medicine components and an application of the aerosol inhalation preparation in replacement of tobacco products. The aerosol inhalation preparation comprises a lung clearing group, an aerosol inhalation group and an aerosol inhalation group, wherein the lung clearing group comprises herba houttuyniae extract, folium mori flavone and total anthraquinone of semen cassiae; a qi tonifying group: ginseng extract and cordycepin; the kidney tonifying group comprises cistanche polysaccharide and eucommia total glycoside; a spleen tonifying and blood circulation promoting group: pachymaran and tanshinone; the tranquilizing and sedating group comprises agilawood volatile oil and lily saponin; an atomization carrier: plant glycerin and propylene glycol; the flavoring agent comprises menthol and glycyrrhizic acid. The invention relates to the technical crossing field of traditional Chinese medicines and modern inhalation preparations. According to the aerosol inhalation preparation containing the traditional Chinese medicine components and the application of the aerosol inhalation preparation in replacing tobacco products, through traditional Chinese medicine compound compatibility and a nanometer wrapping technology, the natural aerosol preparation which has the functions of efficient smoking cessation (the smoking desire is reduced by 78% in 24 hours), lung function repair (IL-6 is reduced by 42%) and good taste acceptability (accepted by 92%) is provided, the lung deposition rate of the aerosol inhalation preparation reaches 65%, and the aerosol inhalation preparation is excellent in stability; and a safe and effective solution is provided for tobacco replacement.

The invention provides a refenasin inhalation solution and a preparation method thereof. The refenasin inhalation solution comprises an active component refenasin, a pH buffer agent, an osmotic pressure regulator and a stabilizer. The stability of the rafenasin inhalation solution under ultrasonic atomization can be remarkably improved, the storage stability is good, and the effect of the better lung deposition rate is achieved.

The present invention discloses a nanoparticle for treating lung diseases, and its preparation method and application. The nanoparticle for treating lung diseases provided by the present invention comprises a nanoparticle carrier and a nucleic acid molecule; the raw materials of the nanoparticle carrier include the TM2 and DOPE, and the molar ratio of the two is 1:2. The nucleic acid-encapsulated nanoparticles provided by the present invention can efficiently deliver nucleic acid molecules to the lungs and downregulate the expression of pathogenic proteins; they can significantly increase the deposition of drugs in the lungs, effectively ensuring the effect after administration, and at the same time have the advantages of simple administration, non-invasiveness, and high safety. It is a highly innovative and efficient lung deposition method with good application prospects in the treatment of lung-related diseases.

The invention provides a nemategravir inhalant and a preparation method and application thereof, and belongs to the technical field of medicines.The nemategravir inhalant comprises nemategravir, water, a surfactant and an auxiliary, has the high lung deposition rate, good stability and low irritation and can overcome the defects of existing nemategravir oral tablets. After the nemategravir inhalant prepared by the embodiment of the invention is inhaled, the residence time of nemategravir in lung tissues can be maintained for more than 12 hours.

The application discloses an inhaled ascorbic acid powder aerosol and a preparation method thereof, and relates to the technical field of inhaled administration, which is composed of ascorbic acid and a diluent, and is in the form of a dry powder, wherein the weight percentage of the ascorbic acid is 10%-100%, and the weight percentage of the diluent is 0-90%; the dry powder aerosol realizes lung target delivery through inhaled administration, has good fluidity and lung deposition effect, and is mainly used for treating acute lung injury, and provides an efficient and safe treatment scheme for lung diseases.

The present invention discloses a rhodomyrtone inhalation suspension and a preparation method thereof. The rhodomyrtone inhalation suspension is obtained by mixing the following raw materials and auxiliary materials in percentage by weight: rhodomyrtone 0.02%-1%, surfactant 0.005%-0.1%, suspending agent 0-2.2%, pH regulator 0.01%-0.03%, flocculant 0.02%-0.04%, stabilizer 0.005%-0.015%, osmotic pressure regulator 0.7%-1.1%, and water as the balance; the surfactant is polysorbate; and the suspending agent is povidone K30 and / or microcrystalline cellulose-sodium carboxymethylcellulose. The inhalation suspension has a high effective lung deposition rate and accurate delivery dose, and can accurately deliver a set dose of rhodomyrtone directly to lung lesions, exerting its antiviral efficacy.